Re: Silke Gillessen, Gerhardt Attard, Tomasz M. Beer, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020;77: 508-47 https://doi.org/10.1016/j.eururo.2020.01.012 (European Urology)

Gillessen et al [1] have presented the report from the Advanced Prostate Cancer Consensus Conference 2019 (APCCC 2019) summarizing the voting of 72 experts on prostate cancer (PC) regarding questions for which randomized trials have not given clear-cut solutions. Among the topics, APCCC 2019 addressed 177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) for patients with multiresistant metastatic castration-resistant PC (mCRPC).